Publications

Babu, MR, Guptha, PM, Yanadaiah, P, Vishwas, S, Gulati, M, Dua, K & Singh, SK 2025, 'Prospects of novel drug delivery systems in treating cerebral palsy' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 269-276.
View/Download from: Publisher's site

Bisht, D, Joshi, DC, Bisht, M, Joshi, N, Azizov, S, Lalhlenmawia, H, Kumar, D, Dua, K, Shetty, SR & Suares, D 2025, 'Natural product-based compounds for chronic respiratory disorders' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 309-333.
View/Download from: Publisher's site

Chawla, PA, Singh, D, Singh, A, Amisha, Raj, ND, Chawla, V & Dua, K 2025, 'Role of novel drug delivery systems in delivering antidepressant drugs to the brain' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 235-245.
View/Download from: Publisher's site

De Rubis, G, MacLoughlin, R, Santos, HA, Shetty, S, Suares, D & Dua, K 2025, 'Preface' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. xxi-xxii.
View/Download from: Publisher's site

Gupta, G, Hussain, MS, Maqbool, M, Bhat, AA, Thapa, R, Rawat, S, Gupta, S, Roshan, S, Chellappan, DK, Singh, SK, Dua, K & Saeid, AB 2025, 'Phthalates and the Gut Microbiome' in Gut Microbiome and Environmental Toxicants, CRC Press, pp. 86-108.
View/Download from: Publisher's site

Kumar, R, Singh, A, Kapoor, B, Hussain, MS, Singh, SK, Dua, K, Dureja, H, Thomas, NV & Gulati, M 2025, 'Nose to brain drug delivery through advanced drug delivery systems' in Novel Drug Delivery Systems in the management of CNS Disorders, Elsevier, pp. 105-119.
View/Download from: Publisher's site

Subramaniyan, V, Gupta, G, Dua, K, Singh, S, Gowthamarajan, K & Narayana Reddy, VVS 2025, 'The gut reaction: Modulating microbial response to toxicants through diet and lifestyle' in Gut Microbiome and Environmental Toxicants: Impact on Human Health, pp. 41-63.
View/Download from: Publisher's site
View description>>

This chapter offers a concise scientific exploration of the intricate relationship between the human microbiome, environmental toxicants, and the impact of dietary and lifestyle choices. Emphasizing the pivotal role of the human microbiome in overall health, the study delves into how lifestyle factors, particularly diet, shape microbial responses to environmental challenges. Focused on the microscopic universe within the body, with the gut as a dynamic hub for diverse microbial communities, the exploration extends beyond bodily confines to investigate complex interactions with environmental toxicants. The study aims to unravel the web of relationships influenced by lifestyle choices, spotlighting practical applications through natural drug molecules like curcumin and substances like karanjin. Curcumin exemplifies its potential to modulate the gut microbiome, fostering a balanced and diverse community essential for overall health. Similarly, karanjin, with antimicrobial properties, emerges as a strategic tool in influencing microbial responses to toxicants, demystifying the human microbiome and emphasizing the role of microbial communities in maintaining physiological harmony. Examples like curcumin and karanjin illustrate the dynamic nature of the microbial universe and its susceptibility to dietary influences. Subsequently, the chapter delves into communication pathways between microbial communities and environmental toxicants, employing real-world examples to illustrate implications for human health. The study concludes by exploring the profound impact of dietary choices on the resilience of the gut microbiome. In summary, this abstract encapsulates the study;s key themes and contributions succinctly.

Subramaniyan, V, Gupta, G, Dua, K, Singh, S, Gowthamarajan, K & Reddy, VVSN 2025, 'The Gut Reaction' in Gut Microbiome and Environmental Toxicants, CRC Press, pp. 41-63.
View/Download from: Publisher's site

Verma, N, Kanojia, N, Thapa, K, Chandel, P & Dua, K 2025, 'Organ-on-a-chip in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems' in Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 267-285.
View/Download from: Publisher's site

Yeung, S, Loo, C-Y, Bani Saeid, A & Lee, W-H 2025, 'Current approaches for the treatment of chronic respiratory disorders and limitations' in De Rubis, G, Santos, HA, Suares, D, MacLoughlin, R, Shetty, S & Dua, K (eds), Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders, Elsevier, pp. 27-49.
View/Download from: Publisher's site
View description>>

The book concludes with a discussion of the current clinical trials and future prospects for the management of CRDs.This is a valuable resource for researchers, clinicians, and other healthcare professionals who are interested in the latest ...

Ashique, S, Mishra, N, Garg, A, Garg, S, Farid, A, Rai, S, Gupta, G, Dua, K, Paudel, KR & Taghizadeh-Hesary, F 2025, 'A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes', The American Journal of Medicine, vol. 138, no. 2, pp. 308-329.
View/Download from: Publisher's site

Bashir, B, Gulati, M, Vishwas, S, Gupta, G, Dhanasekaran, M, Paudel, KR, Chellappan, DK, Anand, K, Negi, P, Singh, PK, Rajput, A, Dua, K & Singh, SK 2025, 'Bridging gap in the treatment of Alzheimer’s disease via postbiotics: Current practices and future prospects', Ageing Research Reviews, vol. 105, pp. 102689-102689.
View/Download from: Publisher's site

Bashir, B, Vishwas, S, Gupta, G, Paudel, KR, Dureja, H, Kumar, P, Cho, H, Sugandhi, VV, Kumbhar, PS, Disouza, J, Dhanasekaran, M, Goh, BH, Gulati, M, Dua, K & Singh, SK 2025, 'Does drug repurposing bridge the gaps in management of Parkinson’s disease? Unravelling the facts and fallacies', Ageing Research Reviews, vol. 105, pp. 102693-102693.
View/Download from: Publisher's site

Benson, H, Heggart, K, Williams, KA, Smit, C & Abela, P 2025, 'Fostering Excellence in Blended Learning, a Mixed Methods Investigation of an Academic Learning Design Support Tool', TechTrends, vol. 69, no. 1, pp. 71-83.
View/Download from: Publisher's site

Bhardwaj, BY, Vihal, S, Pahwa, R, Agarwal, S, Gupta, B, Yang, JC, Chauhan, R, Chellappan, DK, Gupta, G, Singh, SK, Dua, K & Negi, P 2025, 'Recent advancements in xanthan gum-based gastroretentive floating formulations: Chemical modification, production and applications', Carbohydrate Polymers, vol. 348, pp. 122809-122809.
View/Download from: Publisher's site

Birla, D, Khandale, N, Bashir, B, ShahbazAlam, M, Vishwas, S, Gupta, G, Dureja, H, Kumbhar, PS, Disouza, J, Patravale, V, Veiga, F, Paiva-Santos, AC, Pillappan, R, Paudel, KR, Goh, BH, Singh, M, Dua, K & Singh, SK 2025, 'Application of quality by design in optimization of nanoformulations: Principle, perspectives and practices', Drug Delivery and Translational Research, vol. 15, no. 3, pp. 798-830.
View/Download from: Publisher's site

Chaudhari, S, Dalabehera, M, Subudhi, RN, Dua, K, Kaur, M, Paudel, KR & Kumar, J 2025, 'From Nature to Nanotech: Unlocking Berberine’s Therapeutic Approaches', Journal of Drug Delivery Science and Technology, pp. 106924-106924.
View/Download from: Publisher's site

Couceiro, B, Hameed, H, Vieira, ACF, Singh, SK, Dua, K, Veiga, F, Pires, PC, Ferreira, L & Paiva-Santos, AC 2025, 'Promoting health and sustainability: exploring safer alternatives in cosmetics and regulatory perspectives', Sustainable Chemistry and Pharmacy, vol. 43, pp. 101901-101901.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Kokkinis, S, El-Sherkawi, T, Datsyuk, JK, Salunke, P, Gerlach, J & Dua, K 2025, 'Potent phytoceuticals cocktail exhibits anti-inflammatory and antioxidant activity on LPS-triggered RAW264.7 macrophages in vitro', Pathology - Research and Practice, vol. 266, pp. 155770-155770.
View/Download from: Publisher's site

Goyal, R, Kaur, G, Malik, DS, Singh, S, Dua, K, Singh, D & Singh, TG 2025, 'Assessing Anti-Acne Potentials Via in-vitro, Ex-vivo, and in-vivo Models: AComprehensive Approach', Current Drug Targets, vol. 26.
View/Download from: Publisher's site
View description>>

Acne vulgaris is the 8th most commonly prevailing skin disorder worldwide. Its pervasivenesshas been predominant in juveniles, especially males, during adolescence and in femalesduring adulthood. The lifestyle and nutrition adopted have been significantly reported to impactthe occurrence and frequency of acne. It typically occurs over the regions of the forehead, upperchest, and back of the body, which are regions with high proportions of active sebaceous follicles.The market today is flooded with the pool of anti-acne medications (oral, topical/systemic) thatcontain either a single therapeutic agent or a blend targeting multiple pathological pathways. However,the clinical applicability of these preparations is limited due to formulation stability, drugpenetrability, and targeting, the incidence of secondary effects, antibiotic resistance, etc. Moreover,the effectiveness of the former therapies varies as per the type and severity of acne. Therefore,it is necessary to extensively research skin physiology under normal and diseased conditionsso that newer, safer, and more effective medications can be devised. Moreover, their safety and efficacyshould be validated by employing various acne models, and their comparative profilingshould be done with standard marketed anti-acne preparations. Acne models assist to uncover thecomplex disease pathogenesis and identify the potential targets for therapeutic interventions. Thisreview is an attempt to highlight varied in-vitro, ex-vivo, and in-vivo testing procedures done to assessdrug efficacy, track disease progression, and compare test substances with existing treatments.By presenting a unified approach to acne modeling, this review will assist researchers in selectingthe most appropriate model for their specific research goals, helping them to generate valuableand reproducible data to support the development of effective acne therapies.

Haysom‐McDowell, A, Paudel, KR, Yeung, S, Kokkinis, S, El Sherkawi, T, Chellappan, DK, Adams, J, Dua, K & De Rubis, G 2025, 'Recent trends and therapeutic potential of phytoceutical‐based nanoparticle delivery systems in mitigating non‐small cell lung cancer', Molecular Oncology, vol. 19, no. 1, pp. 15-36.
View/Download from: Publisher's site
View description>>

Lung cancer is the leading cause of cancer death globally, with non‐small cell lung cancer accounting for the majority (85%) of cases. Standard treatments including chemotherapy and radiotherapy present multiple adverse effects. Medicinal plants, used for centuries, are traditionally processed by methods such as boiling and oral ingestion, However, water solubility, absorption, and hepatic metabolism reduce phytoceutical bioavailability. More recently, isolated molecular compounds from these plants can be extracted with these phytoceuticals administered either individually or as an adjunct with standard therapy. Phytoceuticals have been shown to alleviate symptoms, may reduce dosage of chemotherapy and, in some cases, enhance pharmaceutical mechanisms. Research has identified many phytoceuticals' actions on cancer‐associated pathways, such as oncogenesis, the tumour microenvironment, tumour cell proliferation, metastasis, and apoptosis. The development of novel nanoparticle delivery systems such as solid lipid nanoparticles, liquid crystalline nanoparticles, and liposomes has enhanced the bioavailability and targeted delivery of pharmaceuticals and phytoceuticals. This review explores the biological pathways associated with non‐small cell lung cancer, a diverse range of phytoceuticals, the cancer pathways they act upon, and the pros and cons of several nanoparticle delivery systems.

Jamwal, A, Sharma, S, Kapoor, VK, Chauhan, R, Dua, K, Dalwal, V, Kumar, A, Prasher, P & Negi, P 2025, 'From Structure to Function: Isatin Derivatives as a Promising Class ofAntiviral Agents', Current Drug Targets, vol. 26.
View/Download from: Publisher's site
View description>>

A range of heterocyclic compounds, including Isatin (oneH-indole-2, 3-dione) and itsby-products, have been shown to represent potential unit blocks in the synthesis of potential medicinal agents. Numerous studies have been carried out on isatin, its synthesis, biological uses,and its chemical composition since when it was discovered. Functionally, these isatin-containingheterocycles have demonstrated antibacterial, antidiabetic, antiviral, antitubercular, and anticancerproperties, among many others. In vitro and In vivo efficaciousness of several Isatin moieties hasbeen assessed in recent years based on their antimicrobial qualities. Isatin has shown great promise as a flexible heterocycle in the realm of drug development in recent years. Many viruses havecaused extensive epidemics during the last 50 years, which have had detrimental effects on social,economic, and health conditions. The current unprecedented SARS-CoV-2 epidemic necessitatesintensive research into the development of potent antiviral medications. It has been shown thatIsatin, a flexible heterocycle, has a great deal of potential for drug development. Appropriatelyfunctionalized Isatin compounds have shown noteworthy and extensive antiviral activitiesthroughout the last fifty years. The goal of this study is to gather all known data on Isatin derivatives' antiviral activity, emphasizing their structure-activity correlations as well as research onmechanistic and molecular modelling. We think that the scientific community will find this review to be a useful tool in the development of more efficient and powerful antiviral treatmentsbased on Isatin scaffolds.

Kakkar, C, Sharma, V, Mannan, A, Gupta, G, Singh, S, Kumar, P, Dua, K, Kaur, A, Singh, S, Dhiman, S & Singh, TG 2025, 'Diabetic Cardiomyopathy: An Update on Emerging Pathological Mechanisms', Current Cardiology Reviews, vol. 21, no. 2.
View/Download from: Publisher's site
View description>>

Diabetic Cardiomyopathy (DCM) is a notable consequence of diabetes mellitus, distinguishedby cardiac dysfunction that occurs separately from coronary artery disease or hypertension.A recent study has revealed an intricate interaction of pathogenic processes thatcontribute to DCM. Important aspects involve the dysregulation of glucose metabolism, resultingin heightened oxidative stress and impaired mitochondrial function. In addition, persistenthigh blood sugar levels stimulate inflammatory pathways, which contribute to the developmentof heart fibrosis and remodelling. Additionally, changes in the way calcium is managedand the presence of insulin resistance are crucial factors in the formation and advancementof DCM. This may be due to the involvement of many molecular mechanistic pathwayssuch as NLRP3, NF-κB, PKC, and MAPK with their downstream associated signaling pathways.Gaining a comprehensive understanding of these newly identified pathogenic pathwaysis crucial in order to design precise therapy approaches that can enhance the results for individualssuffering from diabetes. In addition, this review offers an in-depth review of not justpathogenic pathways and molecular mechanistic pathways but also diagnostic methods, treatmentoptions, and clinical trials.

Kaur, P, Khan, H, Grewal, AK, Dua, K, Singh, SK, Gupta, G & Singh, TG 2025, 'Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease', CNS & Neurological Disorders - Drug Targets, vol. 24, no. 3, pp. 196-207.
View/Download from: Publisher's site
View description>>

Alzheimer’s disease is an ailment that is linked with the degeneration of the brain cells,and this illness is the main cause of dementia. Metabolic stress affects the activity of the brain in ADvia FOXO signaling. The occurrence of AD will significantly surge as the world’s population ages,along with lifestyle changes perceived in current decades, indicating a main contributor to suchaugmented prevalence. Similarly, metabolic disorders of current adulthood, such as obesity, stroke,and diabetes mellitus, have been observed as the risk-causing factors of AD. Environmental influencesinduce genetic mutations that result in the development of several diseases. Metabolic disordersdevelop when individuals are exposed to an environment where food is easily accessible andrequires minimal energy expenditure. Obesity and diabetes are among the most significant worldwidehealth concerns. Obesity arises because of an imbalance between the amount of energy consumedand the amount of energy expended, which is caused by both behavioral and physiologicalfactors. Obesity, insulin resistance syndrome, hypertension, and inflammation are factors that contributeto the worldwide risk of developing diabetes mellitus and neurodegenerative diseases. FOXOtranscription factors are preserved molecules that play an important part in assorted biological progressions,precisely in aging as well as metabolism. Apoptosis, cell division and differentiation, oxidativestress, metabolism, and lifespan are among the physiological processes that the FOXO proteinsare adept at controlling. In this review, we explored the correlation between signaling pathwaysand the cellular functions of FOXO proteins. We have also summarized the intricate role ofFOXO in AD, with a focus on metabolic stress, and discussed the prospect of FOXO as a molecularlink between AD and metabolic disorders.

Khandale, N, Birla, D, Alam, MS, Bashir, B, Vishwas, S, Kumar, A, Potale, Y, Gupta, G, Negi, P, Alam, A, Rehman, ZU, Dua, K, Goh, BH & Singh, SK 2025, 'Quality by design endorsed fabrication of xanthohumol loaded solid nanostructured lipid carrier based powder for effective treatment of Alzheimer's disease in rats', Journal of Drug Delivery Science and Technology, vol. 107, pp. 106792-106792.
View/Download from: Publisher's site

Kolekar, KA, Kumbhar, PS, Vishwas, S, Dua, K & Singh, SK 2025, 'Dissolving microneedles for brain delivery: Recent advances and challenges', Drug Discovery Today, vol. 30, no. 4, pp. 104330-104330.
View/Download from: Publisher's site

Kumbhar, PS, Chavan, R, Darekar, S, Kolekar, K, Sequeira, A, Vishwas, S, Gupta, G, Paudel, KR, Singh, SK, Dua, K, Disouza, J & Patravale, V 2025, 'Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 4, pp. 3213-3240.
View/Download from: Publisher's site

Kumbhar, PS, Kamble, V, Kolekar, KA, Vishwas, S, Kumbhar, P, Patil, KS, Gupta, G, Kharabe, PM, Singh, M, Gurav, S, Chellappan, DK, Singh, SK, Dua, K, Disouza, J & Patravale, V 2025, 'Unraveling the Role of Repurposed Drugs in the Treatment of Acne: Success so Far and the Road Ahead', Drug Development Research, vol. 86, no. 1.
View/Download from: Publisher's site
View description>>

ABSTRACTAcne is a skin disease that impacts 9.4% of the world's population. Available treatments for managing acne include retinoid‐like drugs, antibiotics, corticosteroids, photo, and radiotherapy. Howevere, the aforementioned treatments have certain limitations such as possibility of developing skin cancer from tetracycline, doxycycline, and corticosteroids, microbial resistance to antibiotics, and deadly side effects, and so forth. Repurposing of existing therapeutics having excellent safety profile can be promising way to treat acne efficiently. The repurposed drugs and phytoceuticals from diverse classes have demonstrated promising effects in treating acne. These repurposed drugs have displayed antiacne effectiveness by targeting single or multiple signaling pathways. Various repurposed therapeutics undergoing clinical trials at different phases demonstrated their safety and efficacy in treating acne. Despite being a very good, safe, and less time‐consuming strategy, drug repurposing (DR) faces multiple challenges such as lack of regulatory guidelines, preservation of intellectual property, and clinical validation of claimed therapeutic indication. DR appears to be a viable approach and is likely to offer effective treatment at a reasonable cost in alleviating acne.

Laird, CD, Williams, KA & Benson, H 2025, 'Pharmacists Improving Osteoporosis Management in Long-Term Care Using Fracture Risk Assessments: A Feasibility Study', Journal of the American Medical Directors Association, vol. 26, no. 4, pp. 105494-105494.
View/Download from: Publisher's site

Lambert, M, Taxis, K & Pont, L 2025, 'Impact of Antibiotic Shortages on Antibiotic Utilisation in the Community', Pharmacoepidemiology and Drug Safety, vol. 34, no. 2.
View/Download from: Publisher's site
View description>>

ABSTRACTBackgroundDrug shortages are an increasing and worldwide problem. Oral antibiotics are one of the most used medicines worldwide and have recently been affected by drug shortages. Despite this, little is known about the impact of antibiotic shortages on prescribing practices.AimTo explore the impact of oral antibiotic shortages on national antibiotic utilisation.MethodsA cross‐sectional study of oral antibiotic shortages and antibiotic utilisation was conducted using Australian reimbursement and regulatory data from January 2022 to December 2023. All nationally reimbursed oral antibiotics were included in the study. The number and duration of reported antibiotic shortages per product were determined for each active ingredient. The clinical impact was assessed using national utilisation in Defined Daily Doses per 100 000 inhabitants. Changes in trends were analysed using Joinpoint regression.ResultsShortages were reported for eighteen of the twenty‐one (86%) oral antibiotics reimbursed in Australia. For ten active ingredients, shortages did not coincide with changes in utilisation data. No clear relation between the number and duration of shortages and impact on utilisation was observed. Changes in utilisation coinciding with shortages were observed for eight active ingredients. For cefaclor (−20% decrease in utilisation) and roxithromycin (−26% decrease), the impact of shortages is most clearly reflected by decreases in utilisation. For the other six, minor changes in utilisation were observed coinciding with shortages.ConclusionsAntibiotic shortages were common in Australia during 2022 and 2023. The impact of shortages differs per ...

Mesbahi, Z, Piquer-Martinez, C, Benrimoj, SI, Martinez-Martinez, F, Amador-Fernandez, N, Zarzuelo, MJ, Dineen-Griffin, S & Garcia-Cardenas, V 2025, 'Pharmacists as independent prescribers in community pharmacy: A scoping review', Research in Social and Administrative Pharmacy, vol. 21, no. 3, pp. 142-153.
View/Download from: Publisher's site

Nagar, L, Saini, A, Gandhi, L, Awasthi, R, Dua, K & Dureja, H 2025, 'Nanoemulsion-Based Nystatin Delivery: Formulation and Characterization Studies', BioNanoScience, vol. 15, no. 1.
View/Download from: Publisher's site

Parmal, S, Subbappa, P, Nikam, V, Tarwate, Y, Barhate, K, Wagh, S, Gholap, AD, Dua, K, Singh, SK, Parikh, D, Shaikh, M, Khan, TK & Rajput, A 2025, 'Hyaluronic acid based approaches for wound healing: A comprehensive review', International Journal of Biological Macromolecules, vol. 306, pp. 141625-141625.
View/Download from: Publisher's site

Patel, MN, Patel, AJ, Nandpal, MN, Raval, MA, Patel, RJ, Patel, AA, Paudel, KR, Hansbro, PM, Singh, SK, Gupta, G, Dua, K & Patel, SG 2025, 'Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 3, pp. 2127-2150.
View/Download from: Publisher's site
View description>>

Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions.

Roy, AA, Pokale, R, Mukharya, A, Nikam, AN, Dua, K, Rao, BSS, Seetharam, RN & Mutalik, S 2025, 'Synergizing CRISPR-Cas9 with Advanced Artificial Intelligence andMachine Learning for Precision Drug Delivery: Technological Nexus andRegulatory Insights', Current Gene Therapy, vol. 25.
View/Download from: Publisher's site
View description>>

The evolution of genetic exploration tools, from laborious methods like radiationinduced mutations to the transformative CRISPR-Cas9 system, has fundamentally reshaped geneticresearch and gene editing capabilities. This journey, initiated by foundational techniques such asZFNs and TALENs and culminating in the groundbreaking work of Doudna and Charpentier in2012, has ushered in an era of precise DNA alteration and profound insights into gene functions.The CRISPR/Cas9 system uses the Cas9 enzyme and guides RNA (gRNA) to precisely target andcleave DNA, with subsequent repair via error-prone NHEJ or precise HDR, enabling versatile geneediting. Complementary computational tools like E-CRISP and Azimuth 2.0, alongside advanceddeep learning models like DeepCRISPR, have significantly contributed to refining CRISPR experiments, optimizing gRNA efficiency, and predicting outcomes with greater precision. In clinical applications, CRISPR-Cas9 shows great promise for treating complex genetic disorders like sickle celldisease and β-thalassemia, but faces challenges such as off-target effects, immune responses to viralvectors, and ethical issues in germline editing. Overcoming these challenges requires meticulousexperimentation and robust regulatory frameworks to ensure responsible and beneficial utilizationof the CRISPR-Cas9 technology across diverse fields, including cancer treatment, genetic diseasetherapies, agriculture, and synthetic biology, while continually addressing ethical, safety, and legalconsiderations for its advancement and widespread adoption.

Sadique Hussain, M, Gupta, G, Ghaboura, N, Moglad, E, Hassan Almalki, W, Alzarea, SI, Kazmi, I, Ali, H, MacLoughlin, R, Loebenberg, R, Davies, NM, Kumar Singh, S & Dua, K 2025, 'Exosomal ncRNAs in liquid biopsies for lung cancer', Clinica Chimica Acta, vol. 565, pp. 119983-119983.
View/Download from: Publisher's site

Saini, A, Nagar, L, Panwar, R, Pahwa, R, Dua, K, Dureja, H & Verma, PK 2025, 'Nanostructure-Based Drug Delivery in Alleviating Type 2 Diabetes Mellitus', BioNanoScience, vol. 15, no. 1.
View/Download from: Publisher's site

Sanchez-Molina, AI, Benrimoj, SI, Ferri-Garcia, R, Martinez-Martinez, F, Gastelurrutia, MA, Amador-Fernandez, N & Garcia-Cardenas, V 2025, 'Bridging the gap: Enhancing pharmacist-physiscian collaboration through the provision of comprehensive medication reviews in community pharmacy', Exploratory Research in Clinical and Social Pharmacy, vol. 17, pp. 100555-100555.
View/Download from: Publisher's site

Shaikh, MAJ, Gupta, G, Bagiyal, P, Gupta, S, Singh, SK, Pillappan, R, Chellappan, DK, Prasher, P, Jakhmola, V, Singh, TG, Dureja, H, Singh, SK & Dua, K 2025, 'Enhancing drug bioavailability for Parkinson's disease: The promise of chitosan delivery mechanisms', Annales Pharmaceutiques Françaises, vol. 83, no. 2, pp. 195-210.
View/Download from: Publisher's site

Singh, A, Khan, H, Grewal, AK, Dua, K, Singh, SK & Singh, TG 2025, 'Pharmacological Perspective on the Neurobiology of PI3K-Akt-mTOR Signalling in Opioid Dependence', CNS & Neurological Disorders - Drug Targets, vol. 24.
View/Download from: Publisher's site
View description>>

Abstract:Opioid addiction is a condition of the central nervous system that occurs as a result of usingopiate-based substances, which can be either natural or synthetic chemicals. These have effectsidentical to those of morphine and work by interacting with opioid receptors such as morphine, heroin,opium, buprenorphine, and Oxycontin. Dopamine has been suggested to play a role in themechanisms linked to opioid addiction. Additionally, neurotransmitters such as serotonin, norepinephrine,glutamate, and GABA may also have a significant impact. These processes play a criticalrole in the formation of brain circuits that are involved in the development of addictive behavior.The PI3K-Akt-mTOR pathway is widely recognized as an essential regulator of the effects inducedby neurotransmitters on synaptic plasticity, protein synthesis, and cellular responses. This interplayhas considerable importance in the development and persistence of opioid addiction, impacting severaldomains, including reward processing, stress reactivity, and brain plasticity. The understandingof these neurochemical modifications provides vital insights into the underlying mechanisms of addictionand presents potential pathways for treatments. The review enlisted the clinical trials of differenttypes of opioid addiction or dependence. The review offers a succinct summary of many studiesthat establish a correlation between the PI3K/Akt-mTOR signaling pathway and various receptorsimplicated in multiple forms of opioid-related dependency.

Singh, R, Farooq, SA, Mannan, A, Garg, N, Devi, S, Dua, K & Singh, TG 2025, 'Murraya koenigii Linn. Modulate diabetic neuropathy via attenuation of mechanical hyperalgesia and allodynia in STZ-induced diabetic rats', Obesity Medicine, vol. 54, pp. 100593-100593.
View/Download from: Publisher's site

Singh, S, Sharma, H, Kumar, V, Gupta, G, Patel, S, Patel, A, Dua, K & Kumar Singh, S 2025, 'Method development and validation on RP-HPLC method for estimation of xanthohumol in nanostructured lipid carriers drug delivery systems', Journal of Chromatography B, vol. 1252, pp. 124437-124437.
View/Download from: Publisher's site

Solanki, N, Saini, S, Singh, SK, Paudel, KR, Goh, BH, Dua, K & Dureja, H 2025, 'Central composite designed boswellic acids loaded nanoparticles for enhanced cellular uptake in human lung cancer cell line A549', Journal of Drug Delivery Science and Technology, vol. 105, pp. 106591-106591.
View/Download from: Publisher's site

Soni, D, Garg, Y, Upadhayay, S, Bhatia, A, Basir, B, Singh, SK, Dua, K & Kumar, P 2025, 'Auranofin-loaded chitosan-lipid hybrid nanoparticle protects against rotenone model of Parkinson's disease via modulation of GSK-3β/ Nrf2/HO-1 signaling', European Journal of Pharmacology, vol. 998, pp. 177523-177523.
View/Download from: Publisher's site

Thapa, R, Marianesan, AB, Rekha, A, Ganesan, S, Kumari, M, Bhat, AA, Ali, H, Singh, SK, Chakraborty, A, MacLoughlin, R, Gupta, G & Dua, K 2025, 'Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease', Biogerontology, vol. 26, no. 2.
View/Download from: Publisher's site
View description>>

Abstract Cellular senescence and hypoxia-inducible factor (HIF) signaling are crucial in pulmonary aging and age-related lung diseases such as chronic obstructive pulmonary disease idiopathic pulmonary fibrosis and lung cancer. HIF plays a pivotal role in cellular adaptation to hypoxia, regulating processes like angiogenesis, metabolism, and inflammation. Meanwhile, cellular senescence leads to irreversible cell cycle arrest, triggering the senescence-associated secretory phenotype which contributes to chronic inflammation, tissue remodeling, and fibrosis. Dysregulation of these pathways accelerates lung aging and disease progression by promoting oxidative stress, mitochondrial dysfunction, and epigenetic alterations. Recent studies indicate that HIF and senescence interact at multiple levels, where HIF can both induce and suppress senescence, depending on cellular conditions. While transient HIF activation supports tissue repair and stress resistance, chronic dysregulation exacerbates pulmonary pathologies. Furthermore, emerging evidence suggests that targeting HIF and senescence pathways could offer new therapeutic strategies to mitigate age-related lung diseases. This review explores the intricate crosstalk between these mechanisms, shedding light on how their interplay influences pulmonary aging and disease progression. Additionally, we discuss potential interventions, including senolytic therapies and HIF modulators, that could enhance lung health and longevity.

Truong, J, Abu-Suriya, N, Tory, D, Bahho, R, Ismaiel, A, Nguyen, T, Mansour, A, Nand, V, Saponja, J, Dua, K, De Rubis, G & Parisi, D 2025, 'An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics', European Journal of Drug Metabolism and Pharmacokinetics, vol. 50, no. 1, pp. 1-15.
View/Download from: Publisher's site

Vihal, S, Pundir, S, Rathore, C, Ranjan Lal, U, Gupta, G, Kumar Singh, S, Dua, K, Kumar Chellappan, D & Negi, P 2025, 'Nigella sativa Oil-loaded Ethanolic Vesicular Gel for Imiquimod-induced Plaque Psoriasis: Physicochemical Characterization, Rheological Studies, and In vivo Efficacy', Current Drug Delivery, vol. 22, no. 1, pp. 80-91.
View/Download from: Publisher's site
View description>>

Background:The therapeutic effect of NS oil in mild to moderate psoriasis is limited owingto low play load of thymoquinone (<15 %w/w), irritation, dripping, low viscosity and thus, lesscontact time on the lesions.Aims::This study aimed at developing and characterizing the ethanolic vesicular hydrogel system ofNigella sativa (NS) oil (NS EV hydrogel) for the enhancement of anti-psoriatic activity.Objective:The objective of this study was to develop NS EV hydrogel and evaluate its anti-psoriaticactivity.Methods:The identification and quantification of TQ content in different NS seed extracts and marketedoil were measured by an HPTLC method using n-hexane and ethyl acetate as solvent systems.Preparation of ethanolic vesicles (EVs) was performed by solvent injection method, while its antipsoriaticactivity was evaluated employing an Imiquad (IMQ)-induced plaque psoriasis animal model.Results:A compact HPTLC band was obtained for TQ at an Rf value of 0.651. The calibration plotwas linear in the range of 1-10 μg/spot, and the correlation coefficient of 0.990 was indicative ofgood linear dependence of peak area on concentration. From the different NS sources, the high TQcontent was obtained in the marketed cold press oil, i.e., 1.45±0.08mg/ml. Out of various NS oilloadedEVs, the F6 formulation revealed the smallest particle size (278.1nm), with log-normal sizedistribution (0.459) and adequate entrapment efficiency. A non-uniform shape was observed in thetransmission electron microscopy. The viscosity of F6 formulation hydrogel was 32.34 (Pa·s), whichexhibited plastic behavior. In vivo, efficacy studies demonstrated decreased inflammation...

Wabe, N, Urwin, R, Meulenbroeks, I, Seaman, K, Raban, MZ, Neupane, S, Nguyen, A, Silva, SM, Timothy, A, Batool, N, Pont, L & Westbrook, JI 2025, 'Over- and Underuse of Proton Pump Inhibitors in Nursing Homes: A Multisite Longitudinal Cohort Study', Journal of the American Medical Directors Association, vol. 26, no. 2, pp. 105393-105393.
View/Download from: Publisher's site